Chad May PhD

Chad is the Senior Vice President, Research & Development at Maverick Therapeutics. He is leading preclinical pharmacology and development work on Maverick’s novel T cell retargeting platform. Chad has more than fifteen years of experience in the biotechnology and pharmaceutical industries. Most recently, he was the Senior Director of Targeted Immunotherapy at Pfizer in the Oncology Research Unit where he spearheaded several T cell-engaging bispecific antibody programs. Prior to that, Chad held roles of increasing responsibility at ImClone Systems, which was acquired by Eli Lilly in 2008. During his time there, Chad was a project team leader for several early-stage antibody therapeutics. Chad received his Ph.D. in Immunology from the Weill Cornell Graduate School of Medical Sciences, in a joint program with the Sloan Kettering Institute.